Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Triglycerides measurement
|
1418 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.800 | 1.000 | 22 | 2009 | 2019 | |||||
High density lipoprotein measurement
|
1440 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.800 | 1.000 | 12 | 2009 | 2019 | |||||
Serum HDL cholesterol measurement
|
679 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.700 | 1.000 | 6 | 2009 | 2013 | |||||
Serum total cholesterol measurement
|
1243 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.800 | 1.000 | 9 | 2010 | 2019 | |||||
Hypertriglyceridemia
|
169 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.830 | 1.000 | 6 | 2010 | 2019 | |||||
Low density lipoprotein cholesterol measurement
|
1142 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.800 | 1.000 | 6 | 2010 | 2019 | |||||
Dyslipidemias
|
184 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.020 | 1.000 | 2 | 2010 | 2013 | |||||
Serum LDL cholesterol measurement
|
555 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.700 | 1.000 | 2 | 2010 | 2013 | |||||
Coronary heart disease
|
1178 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.830 | 1.000 | 7 | 2011 | 2018 | |||||
Pseudocholinesterase Measurement
|
568 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||
Vitamin E Assay
|
4 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.800 | 1.000 | 1 | 2011 | 2011 | |||||
Calcification of coronary artery
|
205 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||
Metabolic Syndrome X
|
591 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.810 | 1.000 | 1 | 2012 | 2012 | |||||
Phospholipid measurement
|
306 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.800 | 1.000 | 1 | 2012 | 2012 | |||||
Coronary Artery Disease
|
1577 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.730 | 1.000 | 4 | 2013 | 2018 | |||||
Cardiovascular Diseases
|
711 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.710 | 1.000 | 2 | 2013 | 2019 | |||||
Coronary Arteriosclerosis
|
440 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.020 | 1.000 | 2 | 2013 | 2018 | |||||
Rheumatoid Arthritis
|
2387 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Vitamin measurement
|
4 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.700 | 1.000 | 1 | 2013 | 2013 | |||||
Hypochondroplasia (disorder)
|
42 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Malignant neoplasm of prostate
|
1082 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Prostate carcinoma
|
1168 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Vitamin K Assay
|
6 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.700 | 1.000 | 1 | 2014 | 2014 | |||||
Hyper LDL cholesterolaemia
|
19 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
RDW - Red blood cell distribution width result
|
988 | 0.716 | 0.440 | 11 | 116778201 | 3 prime UTR variant | G/C | snv | 0.82 | 0.700 | 1.000 | 2 | 2016 | 2019 |